Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Capital Markets Day

On June 15th, Oasmia Pharmaceutical AB held a Capital Markets Day in Stockholm.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.

Research

At Oasmia, we’re developing the next generation of drugs with focus on oncology.

Production

At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share

News

Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer.
Read more

Directed issue of warrants in Oasmia Pharmaceutical AB

The board of directors of Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) has resolved on a directed issue of no more than 34,838,709 warrants. Subsequently, all warrants have been...
Read more

Oasmia Pharmaceutical Secures Financing of 108 MSEK

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) a developer of a new generation of drugs within human and veterinary oncology, has agreed to a loan totalling 108 million SEK, of w...
Read more
To news archive